Moody Aldrich Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Moody Aldrich Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-26,180	Closed	-$2.98M	–	188
2021 Q1	$2.98M	Buy	26,180 +448	+2%	+$61K	0.43%	79
2020 Q4	$3.56M	Buy	25,732 +60	+0.2%	+$7.12K	0.57%	78
2020 Q3	$2.11M	Buy	+25,672	New	+$2.13M	0.44%	88
2017 Q1	–	Sell	-9,665	Closed	-$680K	–	96
2016 Q4	$680K	Buy	9,665 +5,135	+113%	+$364K	0.44%	82
2016 Q3	$321K	Buy	+4,530	New	+$289K	0.22%	92

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Moody Aldrich Partners's RARE Position: Q2 2021 in Review

Moody Aldrich Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 26,180 shares — an estimated $2.98M sold.

Moody Aldrich Partners first reported a position in RARE in Q3 2016 and held it in 5 quarters. The position peaked at $3.56M in Q4 2020. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Moody Aldrich Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Moody Aldrich Partners sold 26,180 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $2.98M.
Moody Aldrich Partners first reported a position in Ultragenyx Pharmaceutical in Q3 2016 and held it in 5 quarters.
Moody Aldrich Partners's Ultragenyx Pharmaceutical position peaked at $3.56M in Q4 2020.
241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Moody Aldrich Partners's 13F filing for Q2 2021, filed 4 Aug 2021.